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Aims The purpose of this study was to assess the relationship between calcium scoring (CS) and multi-slice computed tom-
ography coronary angiography (MSCTA) and to determine if MSCTA has an incremental prognostic value to CS.
Methods
and results
In 432 patients (59% male, age 58+11 years) referred for cardiac evaluation owing to suspected coronary artery
disease (CAD), CS and 64-slice MSCTA were performed. The following events were combined in a composite end-
point: all-cause mortality, non-fatal infarction, and unstable angina requiring revascularization. CS was 0 in 147 (34%)
patients, CS 1–99 was present in 122 (28%), CS 100–399 in 75 (17%), CS 400–999 in 56 (13%), and CS  1000 in
32 (7%). MSCTA was normal in 133 (31%) patients, MSCTA 30–50% stenosis was observed in 190 (44%), and
MSCTA 50% stenosis in 109 (25%). During follow-up [median 670 days (25th–75th percentile: 418–895)], an
event occurred in 21 patients (4.9%). After multivariate correction for CS, MSCTA  50% stenosis, the number
of diseased segments, obstructive segments, and non-calcified plaques were independent predictors with an incre-
mental prognostic value to CS.
Conclusion MSCTA provides additional information to CS regarding stenosis severity and plaque composition. This additional
information was shown to translate into incremental prognostic value over CS.
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Introduction
Non-invasive imaging plays an important role in the diagnosis and
prognosis of coronary artery disease (CAD). The development of
non-invasive anatomic imaging techniques, such as coronary
calcium scoring (CS) and multi-slice computed tomography coron-
ary angiography (MSCTA), have resulted in substantially increased
interest in non-invasive imaging of atherosclerosis.
Extensive data are available supporting the value of CS in risk-
stratification and patients with increased CS are generally con-
sidered to have a higher likelihood of future cardiac events. The
majority of data however have been obtained in asymptomatic
patients at low to intermediate risk although the technique may
also be useful in symptomatic patients.1– 4
Direct non-invasive detection of luminal narrowing has become
possible with the introduction of MSCTA. Preliminary studies
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addressing the prognostic value of MSCTA have demonstrated a low
risk for events in case of a normal MSCTA study compared with a
higher risk in the presence of significant CAD on MSCTA.5– 8 Impor-
tantly, MSCTA is not restricted to luminography and the technique
allows simultaneous visualization of the vessel wall. As a result,
also non-stenotic lesions can be identified and even some infor-
mation on plaque composition can be derived.9 This may be an
important feature of the technique as several plaque characteristics
observed on MSCTA have been linked to acute coronary syndromes
in retrospective studies.10,11 Nevertheless, only limited prospective
data are currently available supporting this notion.
Accordingly, both CS and MSCTA may be useful for risk-
stratification in patients with suspected CAD, it is unclear
however if the information regarding stenosis severity and plaque
composition on MSCTA may provide additional prognostic infor-
mation to CS. To answer this clinical question among others, we
have started a prospective registry that addresses the prognostic
value of MSCTA in relation to baseline characteristics as well as
other imaging techniques.12 The purpose of the present study
was to assess the relationship between observations on CS and
MSCTA and to determine whether the information regarding ste-
nosis severity and plaque composition on MSCTA translates into
incremental prognostic value over CS alone.
Methods
Patient selection
The study population consisted of patients with suspected CAD who
were clinically referred for further cardiac assessment because of
chest pain, a positive exercise ECG test, or a high-risk profile for cardi-
ovascular disease as part of an ongoing study protocol addressing the
prognostic value of MSCTA in relation to other imaging techniques.
From this prospective registry, results addressing the incremental prog-
nostic value of MSCTA over myocardial perfusion imaging have been
recently published.12 Patients were enrolled at the University Hospital
in Zurich, Switzerland, and at the Leiden University Medical Center,
The Netherlands. The included patients prospectively underwent a CS
scan followed by MSCTA. Exclusion criteria were: cardiac arrhythmias,
renal insufficiency (defined as a glomerular filtration rate ,30 mL/
min), known hypersensitivity to iodine contrast media, and pregnancy.
In addition, patients with an uninterpretable MSCTA examination
were excluded. The pre-test likelihood of CAD was determined using
the Diamond and Forrester method, with a risk threshold of ,13.4%
for low risk,.87.2% for high risk, and between 13.4 and 87.2% for inter-
mediate risk, as previously described.13 The study was approved by the
Local Ethics Committee of both participating centres.
Calcium scoring and multi-slice computed
tomography coronary angiography protocol
Patients were scanned using a 64-slice CT scanner (Aquillion64,
Toshiba Medical Systems, Tokyo, Japan or General Electrics LightSpeed
VCT, Milwaukee, WI, USA). Before CS and MSCTA examinations, the
patient’s heart rate and blood pressure were monitored. In the
absence of contraindications, patients with a heart rate exceeding
the threshold of 65 b.p.m. were administered beta-blocking medication
(50–100 mg metoprolol oral, or 5–10 mg metoprolol i.v.). Before the
helical scan, a non-enhanced low-dose ECG-gated scan was performed
to measure CS. The CS scan was prospectively triggered at 70% or
75% of the R–R interval and performed using the following scan par-
ameters: 4  3.0 mm or 2.5 mm; gantry rotation time, 350–500 ms;
tube voltage, 120 kV; and tube current, 200–250 mA.
The CS scan was used to determine the start and end positions of
the MSCTA examination. The helical scan was performed using a col-
limation of 64  0.5 mm or 64  0.625 mm. All scan parameters have
been previously published.14,15
Datasets were reconstructed from the retrospectively gated raw
data. Images were reconstructed with an effective slice thickness of
0.3 or 0.5. Coronary arteries were evaluated using the reconstruction
dataset with the least motion artefacts, typically an end-diastolic phase.
The effective dose of the CS and MSCTA scans was estimated from the
dose–length product and an organ weighing factor [k ¼ 0.014 mSv 
(mGy  cm)21] for the chest as the investigated anatomical region.16
Data analysis
Post-processing of the CS and MSCTA examinations was performed on
dedicated workstations (Vitrea2, Vital Images, USA and Advantage, GE
Healthcare, USA). The CS was calculated using the Agatston
method.17 MSCTA angiograms were examined using the axial slices,
curved multiplanar reconstructions, and maximum intensity projections.
Coronary anatomy was assessed in a standardized manner by dividing the
coronary artery tree into 17 segments according to the modified Amer-
ican Heart Association classification. First segments were classified based
on the maximum luminal diameter stenosis. Normal MSCTAwas defined
as completely normal anatomy or minimal wall irregularities,30%, non-
significant CAD was defined as the presence of luminal narrowing with a
maximal luminal diameter stenosis ,50%, and significant CAD was
defined as the presence of an atherosclerotic lesion exceeding the
threshold of 50% maximal luminal diameter stenosis. After assessment
of stenosis severity, plaque composition was determined in all diseased
segments (non-significant or significant CAD on MSCTA). Plaque com-
position was graded as non-calcified plaque (plaques having lower
density compared with the contrast-enhanced lumen), calcified plaque
(plaques with high density), and mixed plaque (containing elements of
both non-calcified and calcified plaques).
Follow-up
Patient follow-up data were gathered using clinical visits or standardized
telephone interviews. A composite endpoint was construed using the
following events: all-cause mortality, non-fatal myocardial infarction,
and unstable angina requiring revascularization. Non-fatal infarction
was defined based on the criteria of typical chest pain, elevated cardiac
enzyme levels, and typical changes on the ECG. Unstable angina was
defined according to the European Society of Cardiology guidelines as
acute chest pain with or without the presence of ECG abnormalities,
and negative cardiac enzyme levels.18 Patients with stable complaints
undergoing an early elective revascularization within 60 days after
imaging with CS and MSCTA were excluded from the survival analysis.
Statistical analysis
Continuous variables were expressed as mean and standard deviation,
and categorical baseline data were expressed in numbers and percen-
tages. Cox regression analysis was used to determine the prognostic
value of CS, and MSCTA variables. First univariate analysis of baseline
CS and MSCTA variables was performed using the composite endpoint
of all-cause mortality, non-fatal infarction, and unstable angina requiring
revascularization. For each variable, a hazard ratio with a 95% confi-
dence interval (95% CI) was calculated. The predictive value of CS
was assessed using binary cut-off values (CS .0, CS 100, CS
400, and CS 1000). For the survival analysis of MSCTA, plaque
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burden [number of (non) significantly diseased segments] and plaque
composition (number of segments with non-calcified, mixed, or
calcified plaque) were analysed as continuous variables. Finally, multi-
variate models were created to assess the independent predictive
value of MSCTA corrected for CS and baseline clinical variables. The
incremental value of MSCTA over CS and baseline clinical variables
was assessed by calculating the global x2 values.
Statistical analyses were performed using SPSS software (version
12.0, SPSS Inc., Chicago, IL, USA). A P-value ,0.05 was considered
statistically significant.
Results
The current study population, derived from our prospective regis-
try,12 consisted of 533 patients presenting with suspected CAD at
the University Hospital Zurich (n ¼ 270) and at the Leiden Univer-
sity Medical Center (n ¼ 263). The demographics in the two popu-
lations were similar. In 24 (4.5%) of these patients, the MSCTA
examination was uninterpretable because of the presence of
motion artefacts, increased noise owing to a high body mass
index, and breathing. In addition, 35 patients (6.9%) were lost to
follow-up, and an early revascularization occurred in 42 (8.3%)
patients. After exclusion of these patients, a total of 432 remained
for further analysis. The baseline characteristics of the patient
population are presented in Table 1. In summary, the average age
of the study cohort was 58+11 years and 58% of patients were
men. A low or intermediate pre-test likelihood was observed in,
respectively, 24% and 65% of patients. A high pre-test likelihood
was observed in 11%.
Calcium scoring and multi-slice
computed tomography coronary
angiography results
The average CS of the cohort was 290+730. Calcium was absent
in 117 (34%) patients, a CS of 1–99 was observed in 122 (28%), a
CS between 100 and 399 in 75 (17%), a CS between 400 and 999
in 56 (13%), and a CS  1000 was present in 32 (7%) patients.
MSCTA was normal in 133 (31%) patients, and atherosclerosis
(non-significant or significant CAD) was present in the remaining
299 (69%) patients. Among the patients with atherosclerosis, non-
significant CAD was observed in 190 (44%), and significant CAD
was present in 109 (25%) patients. For the GE scanner, the esti-
mated average radiation dose for the MSCTA protocol was
18.3+ 5.9 mSv, and the average radiation dose for the CS proto-
col was 1.2+0.6 mSv. For the Toshiba scanner, the estimated
average radiation dose for the coronary angiography protocol
was 17.6+ 5.6 mSv and the estimated radiation dose for the CS
protocol was 1.5+0.7 mSv.
Relationship between calcium scoring and
stenosis severity and plaque composition
assessed on multi-slice computed
tomography coronary angiography
Stenosis severity
Figure 1 illustrates the MSCTA findings in patients with increasing CS
values. In patients without any coronary calcium, MSCTA was
normal in 80%. Non-calcified plaque was observed in the remaining
20% of patients (7% of the total study population). Importantly, sig-
nificant CAD was observed in 4% of patients with a CS of 0. An
example of a patient with a CS of 0 and a large non-calcified
plaque on MSCTA, confirmed on conventional coronary angiogra-
phy is shown in Figure 2. In patients with coronary calcifications, non-
significant and significant lesions were present in all but a few
patients. However, the relationship between CS and significant
CAD on MSCTA was less evident. Particularly, in patients with an
intermediate CS between 100 and 1000, significant CAD was
observed in approximately 50% of patients. In patients with a high
CS  1000, non-significant CAD was observed in 30% of patients.
Plaque composition
MSCTA enables assessment of plaque composition in addition to
stenosis severity. Figure 3 shows the distribution of segments
with non-calcified plaque, mixed plaque, and calcified plaque in
each CS category as a percentage of the total diseased segments.
In patients with CS of 0, all 76 diseased segments showed non-
calcified plaque. With increasing CS categories, the percentage of
segments with calcified plaque contributing to the total of diseased
segments increased. MSCTA was however able to identify a large
proportion of diseased segments with elements of non-calcified
plaque (either mixed plaque or non-calcified plaque) in each
category.
Follow-up results
A median follow-up time of 670 days (25th–75th percentile: 418–
895) was obtained, during which the composite endpoint occurred
in 21 patients (4.9%). All-cause death was reported in six patients
(1.4%), whereas non-fatal myocardial infarction occurred in eight
patients (1.8%), and seven patients (1.6%) were revascularized
owing to unstable angina pectoris.
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Table 1 Patient characteristics
Total (n5 432)
Gender (male) 59%
Age (years) 58+11
Risk factors
Diabetes 121 (28%)
Hypertension 244 (57%)
Hypercholesterolaemia 170 (39%)
Family history of CAD 157 (36%)
Current smoking 119 (28%)
Obesity (BMI  30) 92 (21%)
Pre-test likelihood of CAD
Low 102 (24%)
Intermediate 281 (65%)
High 49 (11%)
BMI, body mass index; CAD, coronary artery disease.
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Figure 1 The relationship between increasingly higher calcium scoring categories and the prevalence of normal coronary anatomy (comple-
tely normal or minor wall irregularities), non-significant CAD (MSCTA,50% stenosis) and significant CAD (MSCTA50% stenosis) on
MSCTA. CAD, coronary artery disease; CS, calcium score; MSCTA, multi-slice computed tomography.
Figure 2 Case example of a 54-year-old male patient presenting with atypical complaints. On CS no coronary calcifications were observed.
However, a large significant non-calcified plaque was detected in the left anterior descending artery on MSCTA (A–C), which was confirmed on
conventional coronary angiography (D). CS, calcium score; MSCTA, multi-slice computed tomography.
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Survival analysis
Univariate analysis of CS and MSCTA categories is shown in
Table 2. Within the CS cut-off categories CS  100, CS  400,
and CS  1000 were significant predictors of events. The highest
hazard ratio was observed when using a cut-off of 1000. On
MSCTA several variables reached statistical significance. The
presence of any stenosis (non-significant (30–50% stenosis) or sig-
nificant (50% stenosis) as well as the presence of significant CAD
(50% stenosis) were both strong significant predictors. When
regarding plaque burden, both the number of diseased segments
as well as the number of segments with significant CAD were sig-
nificant univariate predictors. When regarding plaque composition,
the number of segments with non-calcified plaque and the number
segments with mixed plaque were also significant predictors of
events. The number of segments with calcified plaque was not a
significant predictor of events.
Event rates
The annualized event rate in patients without any coronary calcium
was 1.1%. Increasingly higher CS was associated with increasingly
higher annualized event rates, the annualized event rate was 1.4%
in patients with a CS 1–99, 3.7% in patients with a CS 100–399,
and 4.8% in patients with a CS 400–999. The highest annualized
event rate of 8.5% was observed in patients with a CS  1000.
When regarding MSCTA, an event rate of 0.8% was observed in
patients with a normal MSCTA (completely normal or minor wall
irregularities); while in patients with atherosclerosis (non-
significant and/or significant CAD) the annualized event rate was
3.5%. In patients with non-significant CAD, the annualized event
rate was 2.1%, vs. 5.9% in patients with significant CAD.
Independent and incremental prognostic
value of multi-slice computed
tomography coronary angiography
over calcium scoring
To determine the independent prognostic value of MSCTA, multi-
variate models were created including all MSCTA variables cor-
rected for age, gender, and CS  1000. Table 3 shows that the
presence of significant CAD, the number of diseased segments,
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Table 2 Univariate calcium scoring (CS) and
multi-slice computed tomography coronary
angiography (MSCTA) predictors of coronary events
HR (95% CI) P-value
CS
Calcium score (per unit increase
in CS)
1.00 (1.00–1.01) 0.019
Any calcium 3.2 (0.9–10.9) 0.062
Calcium score 100 3.9 (1.5–10.2) 0.005
Calcium score 400 3.5 (1.5–8.3) 0.004
Calcium score 1000 4.1 (1.5–11.3) 0.006
MSCTA
Atherosclerosis 4.3 (1.0–18.6) 0.048
Significant CAD 3.9 (1.7–9.3) 0.002
No. of diseased segments 1.2 (1.08–1.3) ,0.001
No. of segments with significant
CAD
1.4 (1.2–1.6) ,0.001
No. of segments with non-calcified
plaque
1.2 (1.07–1.4) 0.003
No. of segments with mixed plaque 1.3 (1.07–1.5) 0.005
No. of segments with calcified
plaque
1.09 (0.9–1.3) 0.254
CAD, coronary artery disease; HR, hazards ratio; CI, confidence interval.
Figure 3 The distribution of segments with non-calcified plaque, mixed plaque, and calcified plaque as a percentage of the total diseased
segments on MSCTA per CS category. In patients with a CS of 0, all 76 diseased segments showed non-calcified plaques. With increasing
CS categories, the percentage of diseased segments with calcified plaque increased. Nevertheless, non-calcified plaque and mixed plaque
were still observed in a large proportion of diseased segments in each CS category. CS, calcium score; MSCTA, multi-slice computed tomogra-
phy coronary angiography.
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obstructive segments, segments with non-calcified plaque, and the
number of segments with mixed plaque remained independent
predictors. Furthermore, plaque burden and plaque composition
provided incremental prognostic value over clinical variables and
MSCTA as shown in Figures 4 and 5. These results suggest that
MSCTA may provide additional prognostic information. In particu-
lar, the number of segments with significant CAD and the number
of segments with non-calcified plaque provided significant incre-
mental prognostic value over CS. The number of mixed plaques
provided borderline significant (P ¼ 0.058) incremental prognostic
value to CS.
Discussion
The main finding of the current study was that MSCTA may
provide additional anatomic information regarding stenosis severity
and plaque composition compared with CS. Furthermore, this
information offers important prognostic information which is
incremental to CS for risk-stratification.
Calcium scoring and multi-slice
computed tomography coronary
angiography for atherosclerosis detection
In asymptomatic patients, CS may be useful to identify the pres-
ence of atherosclerosis and thus identify patients that may be at
higher risk than recognized based on traditional risk assessment.19
Vice versa, absence of calcium in general implies a low likelihood
of events.20 However, in a small proportion of patients with a
negative CS, non-calcified plaque has been observed.21,22 Indeed,
in certain subpopulations, such as those at higher risk or in symp-
tomatic patients, the prevalence of non-calcified plaque may be
higher.23–25 Akram et al.23 specifically studied the relationship
between symptomatic status and the prevalence of non-significant
and significant CAD in patients with a CS of 0 and observed 22%
non-significant and significant CAD and 8% significant CAD in
symptomatic patients. In the current study, non-significant or sig-
nificant CAD was identified on MSCTA in 20% of patients with a
CS of 0, whereas significant CAD was observed in 4%. Accordingly,
Figure 4 Bar graphs illustrating the incremental prognostic
value (depicted by x2 value on the y-axis) of significant CAD
(50% stenosis) on MSCTA and plaque burden (defined as the
number of diseased or segments with significant CAD on
MSCTA) over age, gender, and CS. CS has a significant incremen-
tal prognostic value over age and gender (#). A further incremen-
tal prognostic value over age, gender, and CS was observed with
the addition of MSCTA (*). CS, calcium score; MSCTA, multi-
slice computed tomography.
Figure 5 Bar graphs illustrating the incremental prognostic
value (depicted by x2 value on the y-axis) of MSCTA plaque com-
position variables over age, gender, and CS. CS has a significant
incremental prognostic value over age and gender (#). A
further incremental prognostic value over age, gender, and CS
was observed with the addition of MSCTA (*). CS, calcium
score; MSCTA, multi-slice computed tomography.
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Table 3 Multivariate models for the prediction of
coronary events
HR (95% CI) P-value
Model 1*
Atherosclerosis 4.5 (0.9–21.3) 0.056
Calcium score  1000 4.0 (1.3–12.4) 0.016
Model 2*
Significant CAD 3.6 (1.4–9.4) 0.009
Calcium score  1000 2.9 (0.9–9.3) 0.064
Model 3*
No. of diseased segments 1.2 (1.1–1.3) 0.006
Calcium score  1000 2.0 (0.6–6.9) 0.268
Model 4*
No. of segments with significant CAD 1.3 (1.1–1.5) 0.003
Calcium score  1000 2.6 (0.7–9.3) 0.148
Model 5*
No. of segments with non-calcified
plaque
1.3 (1.1–1.4) 0.001
Calcium score  1000 5.8 (1.9–18.2) 0.003
Model 6*
No. of segments with mixed plaque 1.2 (1.0–1.4) 0.039
Calcium score  1000 3.6 (1.1–11.6) 0.029
*Corrected for age and gender.
CAD, coronary artery disease; HR, hazard ratio; CI, confidence interval.
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particularly in symptomatic populations, a small proportion of
patients with atherosclerosis may not be recognized by CS.
Considering patients with evidence of coronary calcifications, a
positive association has been observed between CS and the pres-
ence of significant CAD on MSCTA and conventional coronary
angiography.26,27 Indeed, in the current study, the prevalence of
significant CAD paralleled increasing CS categories. Nevertheless,
in a substantial proportion of patients with extensive calcifications,
significant CAD was absent on MSCT, indicating somewhat lower
specificity of CS to diagnose significant CAD in line with previous
investigations.28,29 Since particularly in symptomatic patients identi-
fication of significant CAD is of importance for guiding clinical
management (including decisions for potential revascularization),
MSCTA may provide incremental diagnostic information to CS in
this regard.
Prognostic value of calcium scoring and
multi-slice computed tomography
coronary angiography
A considerable amount of evidence regarding risk-stratification is
available with CS in asymptomatic patients.19,20,30– 33 Although
less frequently studied, also in symptomatic patients, CS has
been shown to provide important prognostic information.1– 4 In
the study by Detrano et al.,1 a six times higher event rate was
observed in patients with a CS above the median compared to
those with a CS below the median.
The prognostic value of MSCTA has been studied less exten-
sively.5– 8 In the largest study thus far by Min et al.,6 a cohort of
1127 patients undergoing 16-slice MSCT was evaluated. The prog-
nostic value of the Duke Prognostic Coronary Artery Disease
Index was assessed and event rates for all-cause mortality
ranging between 0.3% for none or mild atherosclerosis (stenosis
,50%) to 15% for mild to moderate left main disease were
observed in a period of 2 years. Similar findings were reported
in smaller studies by Gilard et al.5 and Pundziute et al.7 Further-
more, recently published results from our current prospective reg-
istry have demonstrated an incremental prognostic value of
MSCTA over myocardial perfusion imaging using single-photon
emission computed tomography.12
To our knowledge, the current study is the first in assessing the
incremental prognostic value of both stenosis severity and plaque
composition on MSCTA over CS. In a previous study however, the
incremental value of plaque burden derived by non-invasive coron-
ary angiography with electron beam computed tomography over
CS was assessed by Ostrom et al.34 The authors showed that
plaque burden, defined as the number of non-significantly or sig-
nificantly diseased vessels, had independent and incremental
value in predicting all-cause mortality independent of age,
gender, conventional risk factors, and CS. Similar findings were
recently reported by Rubinshtein et al.8 Accordingly, in combi-
nation with our own observations, it appears that non-invasive
measures of the extent and severity of stenosis provide incremen-
tal prognostic information over CS.
Importantly, assessment of plaque composition may further
enhance risk-stratification. However, only limited prospective
data are available addressing the potential relationship between
plaque composition on MSCTA and outcome. When exploring
plaque composition in the current study, the number of segments
with non-calcified plaque as well as the number of segments with
mixed plaque was shown to be independently associated with
increased risk for events. Interestingly, no such relation was
observed for the number of segments with calcified plaque. An
explanation may be that CS is more accurate at quantifying
calcium burden. Furthermore, when regarding only the number
of calcified plaques on MSCT, the calcium in mixed plaques is
disregarded. Another explanation may be that non-calcified
plaque is more important from a prognostic standpoint. Currently,
two previous studies have addressed the prognostic value of
plaque composition assessed by MSCTA.7,12 Pundziute et al.7
observed that the number of mixed plaques was a significant pre-
dictor when corrected for baseline clinical variables. In addition,
we recently showed that plaque composition on MSCTA provides
incremental prognostic value over myocardial perfusion imaging.12
Limitations
Even though the diagnostic accuracy of MSCTA is high, uninterpre-
table images are still encountered in a small percentage of patients
owing to motion because of high or irregular heart rates or breath-
ing during the examination. It is however anticipated that the
number of uninterpretable studies will continue to decrease with
newer generation scanners. Another potential limitation of
MSCTA is the use of iodinated contrast media. As a result
MSCTA is contraindicated in patients with renal insufficiency or
known hypersensitivity to iodine contrast media. Currently,
64-slice MSCTA is still associated with a significantly higher radi-
ation exposure than CS, although the radiation dose of MSCTA
will decrease with the use of dedicated dose-reduction techniques
that have recently become available.35 –38
Conclusion
Non-invasive anatomic imaging using CS and MSCTA is useful for
the detection of atherosclerosis; MSCTA however provides
additional information to CS regarding stenosis severity and
plaque composition. This additional information was shown to
translate into incremental value for risk stratification.
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